Only two prospective clinical trials (RTOG 0424 and EORTC 22033–26033) have reported on MGMT promotor status among patients with glioma WHO grade II, and both trials have produced inconclusive evidence whether MGMT promotor methylation is independent from other molecular markers5,6. The gene discussed is MGMT; the disease is central nervous system cancer.